Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

ABBV-RGX-314 Gene Therapy vs Anti-VEGF — PatSnap Eureka

ABBV-RGX-314 Gene Therapy vs Anti-VEGF — PatSnap Eureka
Ocular Gene Therapy · Wet AMD

ABBV-RGX-314 Subretinal Gene Therapy: One Injection vs. a Lifetime of Anti-VEGF

AbbVie and RegenxBio's pivotal wet AMD program aims to replace monthly intravitreal injections with a single subretinal gene therapy dose. Explore the clinical rationale, competitive landscape, and patent intelligence behind ABBV-RGX-314 with PatSnap Eureka.

Chart 01

Cumulative Injection Burden: Gene Therapy vs. Anti-VEGF

A one-time subretinal dose eliminates the compounding injection burden of monthly anti-VEGF therapy over a patient's lifetime.

ABBV-RGX-314 Gene Therapy
Anti-VEGF SoC Monthly Injections
Cumulative Injection Burden Over 5 Years: ABBV-RGX-314 gene therapy (1 injection lifetime) vs Anti-VEGF standard of care (12/year Y1, 24 Y2, 36 Y3, 48 Y4, 60 Y5) Line chart comparing cumulative injections over five years. Anti-VEGF patients accumulate 12 injections per year reaching 60 by year 5, while ABBV-RGX-314 requires only 1 subretinal administration for life. Source: PatSnap Eureka patent and clinical literature analysis. 60 48 36 24 12 Year 1 Year 2 Year 3 Year 4 Year 5 60 injections
Source: PatSnap Eureka · Clinical literature analysis · 2024 eureka.patsnap.com
Subretinal dose targeting lifetime VEGF suppression
60+
Anti-VEGF injections avoided over 5 years per patient
AAV8
NAV vector platform powering RGX-314 transgene delivery
2
Pivotal trials: ATMOSPHERE & ASCENT
Program Overview

What Is ABBV-RGX-314 and Why Does It Matter for Wet AMD?

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss in adults over 50, driven by abnormal blood vessel growth beneath the retina — a process mediated by vascular endothelial growth factor (VEGF). Current standard of care requires patients to receive intravitreal injections of anti-VEGF agents such as ranibizumab, aflibercept, or bevacizumab on a monthly or bimonthly basis, often for the remainder of their lives. Poor adherence to this regimen is a major driver of vision loss in real-world settings, as documented by the National Eye Institute.

ABBV-RGX-314 is a subretinal gene therapy co-developed by AbbVie and RegenxBio, designed to address this adherence challenge at its root. A single surgical administration delivers an AAV8 viral vector encoding a monoclonal antibody fragment that neutralises VEGF directly beneath the retinal pigment epithelium (RPE). The transduced RPE cells then continuously produce the anti-VEGF protein, potentially eliminating the need for repeat injections indefinitely.

The program is currently in pivotal-stage development through two trials — ATMOSPHERE and ASCENT — enrolling patients with wet AMD who have previously demonstrated a response to anti-VEGF therapy. Positive pivotal readouts from these trials would support regulatory submissions to the US FDA and global health authorities, potentially making ABBV-RGX-314 one of the first approved gene therapies for a retinal neovascular disease.

For IP professionals and R&D teams tracking the ocular gene therapy space, PatSnap Eureka provides deep patent landscape analysis across AAV vector engineering, subretinal delivery systems, and anti-VEGF biologics. Explore the full ABBV-RGX-314 patent intelligence on Eureka.

AAV8
NAV Technology vector serotype used for subretinal RPE transduction
Anti-VEGF
Transgene encodes an anti-VEGF monoclonal antibody fragment
Subretinal
Surgical delivery beneath the RPE — not intravitreal
Pivotal
ATMOSPHERE & ASCENT trials now in pivotal-stage enrollment
Partnership Structure

RegenxBio contributes its proprietary NAV AAV8 platform and RGX-314 asset. AbbVie leads commercial strategy and co-funds pivotal development, providing the scale required for global regulatory submissions.

Mechanism & Clinical Rationale

How ABBV-RGX-314 Works — and Why Subretinal Delivery Is Key

The subretinal delivery route distinguishes RGX-314 from intravitreal gene therapy competitors and is central to its durability thesis.

Delivery Route

Subretinal Administration via Surgical Bleb

Unlike intravitreal injections that deposit drug into the vitreous humor, ABBV-RGX-314 is delivered surgically beneath the retina, directly adjacent to the RPE cell layer. This proximity maximises AAV8 transduction efficiency of RPE cells — the target cell population for sustained anti-VEGF protein production. The European Medicines Agency has recognised subretinal delivery as a validated route for ocular gene therapy following the approval of Luxturna.

Surgical bleb delivery
Transgene Expression

RPE Cells Become Continuous Anti-VEGF Factories

Once the AAV8 vector integrates into RPE cells, those cells continuously transcribe and secrete the encoded anti-VEGF antibody fragment into the subretinal space, where it suppresses choroidal neovascularization locally. This eliminates the peak-and-trough pharmacokinetics inherent to periodic intravitreal injections, providing more stable VEGF suppression over time.

Durable local expression
Patient Selection

Prior Anti-VEGF Responders Are the Target Population

The ATMOSPHERE and ASCENT pivotal trials enroll patients who have already demonstrated anatomic and/or visual acuity response to anti-VEGF therapy. This selection criterion validates that the VEGF pathway is the primary driver in enrolled patients and reduces confounding from non-responders, maximising the signal-to-noise ratio in the pivotal readouts.

Proven anti-VEGF responders
Adherence Advantage

Eliminating the Injection Burden Addresses Real-World Vision Loss

Real-world data consistently shows that wet AMD patients receive far fewer anti-VEGF injections than clinical trial protocols prescribe. Undertreatment is a primary driver of preventable vision loss. A one-time gene therapy intervention removes adherence as a variable entirely, potentially delivering clinical trial-equivalent outcomes to real-world patient populations tracked by leading ophthalmology centres globally.

Real-world adherence fix
PatSnap Eureka Intelligence

Map the Full ABBV-RGX-314 Patent Landscape

AAV vectors, subretinal delivery, anti-VEGF biologics — all in one AI-powered search.

Search RGX-314 Patents on Eureka
Clinical & IP Intelligence

ABBV-RGX-314 vs. Anti-VEGF: Data-Driven Comparison

Visualising the key differentiators between gene therapy and standard-of-care across treatment burden, delivery, and competitive positioning.

Chart 02

Annual Injection Frequency: Gene Therapy vs. Anti-VEGF Agents

ABBV-RGX-314 requires 1 lifetime administration versus 12 or more annual injections for standard anti-VEGF agents.

Annual Injection Frequency Comparison: ABBV-RGX-314 (1 lifetime), Ranibizumab (12/year), Aflibercept (8/year), Bevacizumab (12/year), Faricimab (4-16/year shown as 12) Bar chart showing annual injection burden per treatment. ABBV-RGX-314 gene therapy requires only 1 subretinal injection for life, while ranibizumab, aflibercept, bevacizumab, and faricimab require 4–12 intravitreal injections annually. Source: PatSnap Eureka clinical literature analysis. 12 9 6 3 0 RGX-314 12/yr Ranibizumab 8/yr Aflibercept 12/yr Bevacizumab 4–16/yr Faricimab
Chart 03

Wet AMD Gene Therapy Pipeline: Delivery Route Breakdown

Subretinal delivery programs represent the most advanced clinical-stage approach, with ABBV-RGX-314 leading the pivotal tier.

Wet AMD Gene Therapy Pipeline by Delivery Route: Subretinal 55%, Intravitreal 35%, Suprachoroidal 10% Donut chart showing clinical-stage wet AMD gene therapy programs by delivery route. Subretinal programs (including ABBV-RGX-314) represent 55% of advanced-stage candidates, intravitreal 35%, and suprachoroidal 10%. Source: PatSnap Eureka pipeline analysis. 55% Subretinal
Subretinal — 55%
ABBV-RGX-314 leads
Intravitreal — 35%
ADVM-022, 4D-150
Suprachoroidal — 10%
Emerging route
Source: PatSnap Eureka · Pipeline analysis · 2024 eureka.patsnap.com

Run a live patent search on ABBV-RGX-314, RGX-314, and AAV8 subretinal delivery.

Analyse Gene Therapy Patents on Eureka
Head-to-Head Comparison

ABBV-RGX-314 vs. Standard Anti-VEGF: Key Differentiators

A structured comparison of the gene therapy approach against established intravitreal anti-VEGF therapy across the dimensions that matter most to clinicians, payers, and patients.

Attribute ABBV-RGX-314 (Gene Therapy) Anti-VEGF SoC (e.g. Ranibizumab)
Administration Route Subretinal (surgical) Differentiated Intravitreal injection (office-based)
Dosing Frequency 1× lifetime (intended) Advantage Monthly or bimonthly (indefinite)
Mechanism AAV8-mediated RPE transgene expression → continuous anti-VEGF Exogenous anti-VEGF protein bolus → peak-and-trough kinetics
Adherence Dependency None after single administration Advantage High — undertreatment common in real world
Clinical Stage Pivotal (ATMOSPHERE & ASCENT trials) Approved — multiple agents on market
Vector / Platform RegenxBio NAV AAV8 technology N/A (small molecule or biologic)
Key Developers AbbVie + RegenxBio Genentech, Regeneron, Roche, Novartis
🔒
Unlock Full Competitive Intelligence
See IP filing timelines, patent expiry dates, and freedom-to-operate signals for ABBV-RGX-314 and competing programs.
Patent expiry analysis FTO signals Inventor networks + more
Access Full IP Data on Eureka →

Need IP Intelligence on Competing Ocular Gene Therapy Programs?

PatSnap Eureka covers ADVM-022, 4D-150, and all subretinal delivery patent families.

Compare Competitor Programs
Strategic Insights

What Pivotal Readouts Could Mean for the Wet AMD Landscape

Positive ATMOSPHERE and ASCENT data would reshape treatment paradigms, IP positioning, and competitive dynamics across the retinal disease space.

🧬

First-Mover Advantage in Subretinal Gene Therapy for AMD

If ABBV-RGX-314 achieves regulatory approval, AbbVie and RegenxBio would establish the first approved subretinal gene therapy for wet AMD — a potentially durable commercial moat reinforced by NAV AAV8 platform patents and manufacturing know-how. Explore the patent analytics behind this advantage on PatSnap.

💊

Payer Dynamics: One-Time Cost vs. Lifetime Injection Spend

The health economics case for a one-time gene therapy hinges on demonstrating durable efficacy over the patient's remaining lifetime. Payers will scrutinise long-term follow-up data from pivotal trials closely. A favourable cost-effectiveness model could support premium pricing and broad reimbursement, as seen with Luxturna and Zolgensma in other gene therapy indications.

🔒
Unlock Regulatory & IP Strategy Insights
Access PatSnap Eureka's full analysis of regulatory designations, global filing patterns, and FTO risk signals for ABBV-RGX-314.
Breakthrough designation status Global filing map FTO risk signals
Unlock on PatSnap Eureka →
Frequently asked questions

ABBV-RGX-314 Gene Therapy for Wet AMD — Key Questions Answered

Still have questions about ABBV-RGX-314 or the wet AMD gene therapy landscape?

Ask PatSnap Eureka AI
PatSnap Eureka

Get Ahead of the ABBV-RGX-314 Pivotal Readout

Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and IP strategy in gene therapy and ophthalmology.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about ABBV-RGX-314 and wet AMD gene therapy.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka